KOTAI Biotechnologies

KOTAI Biotechnologies, Inc. specializes in immuno-informatics, leveraging artificial intelligence and big data analysis to develop next-generation therapeutics. The company collaborates with researchers and medical professionals to create personalized cancer immunotherapies using regenerated T cells derived from induced pluripotent stem (iPS) cells. Additionally, KOTAI Biotechnologies participates in clinical research on COVID-19, analyzing the immune profiles of patients to contribute to the global understanding and treatment of the disease. The company operates in the biotechnology sector, primarily serving researchers, medical professionals, and healthcare institutions. Its business model revolves around providing advanced data analysis services and collaborative research opportunities, generating revenue through service fees and research grants.

Keywords: immuno-informatics, AI, big data, 3D molecular simulation, cancer immunotherapy, iPS cells, COVID-19, immune profile, biotechnology, healthcare.